Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Autor: | Sorio, R. Roemer-Becuwe, C. Hilpert, F. Gibbs, E. García, Y. Kaern, J. Huizing, M. Witteveen, P. Zagouri, F. Coeffic, D. Lück, H.-J. González-Martín, A. Kristensen, G. Levaché, C.-B. Lee, C.K. Gebski, V. Pujade-Lauraine, E. |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
ISSN: | 0097-6911 |
Popis: | Background The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC). Methods Patients with PROC were randomised to receive investigator-selected single-agent chemotherapy alone or with bevacizumab. Post-hoc exploratory analyses assessed efficacy, safety and patient-reported outcomes according to age |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...